BD-1008 je antagonist sigma receptora, koji blokira efekte kokaina u studijama na životinjama. On potencijalno može da bude koristan u razvoju antidota za lečenje kokainskog predoziranja.[1][2][3][4]

BD-1008
IUPAC ime
2-(3,4-dichlorophenyl)-N-methyl-N-(2-pyrrolidin-1-ylethyl)ethanamine
Identifikatori
CAS broj138356-08-8 ДаY
ATC kodnone
PubChemCID 126388
Hemijski podaci
FormulaC15H22Cl2N2
Molarna masa301.254 g/mol
  • Clc1ccc(cc1Cl)CCN(C)CCN2CCCC2

Vidi još

уреди

Reference

уреди
  1. ^ Monnet FP, de Costa BR, Bowen WD (1996). „Differentiation of sigma ligand-activated receptor subtypes that modulate NMDA-evoked [3H]-noradrenaline release in rat hippocampal slices”. British Journal of Pharmacology. 119 (1): 65—72. PMC 1915737 . PMID 8872358. 
  2. ^ Matsumoto RR, McCracken KA, Pouw B, Miller J, Bowen WD, Williams W, De Costa BR (2001). „N-alkyl substituted analogs of the sigma receptor ligand BD1008 and traditional sigma receptor ligands affect cocaine-induced convulsions and lethality in mice”. European Journal of Pharmacology. 411 (3): 261—73. PMID 11164383. 
  3. ^ Matsumoto RR, McCracken KA, Friedman MJ, Pouw B, De Costa BR, Bowen WD (2001). „Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice”. European Journal of Pharmacology. 419 (2-3): 163—74. PMID 11426838. doi:10.1016/S0014-2999(01)00968-2. 
  4. ^ Matsumoto RR, Gilmore DL, Pouw B, Bowen WD, Williams W, Kausar A, Coop A (2004). „Novel analogs of the sigma receptor ligand BD1008 attenuate cocaine-induced toxicity in mice”. European Journal of Pharmacology. 492 (1): 21—6. PMID 15145701. doi:10.1016/j.ejphar.2004.03.037. 


 Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).